958P - Does the presence of hepatitis virus B & C influence the evolution of diffuse large B-cell lymphomas?

Date 28 September 2014
Event ESMO 2014
Session Poster Display session
Topics Lymphomas
Cancer in Special Situations
Presenter Judit Rubio-Martínez
Citation Annals of Oncology (2014) 25 (suppl_4): iv327-iv339. 10.1093/annonc/mdu339
Authors J. Rubio-Martínez1, F. Franco1, E. Almagro-Casado2, D. Pérez-Callejo3, M. Palka4, A. Gonzaga1, R. Núñez1, A.C. Sanchez Ruiz5, M. Méndez García4, C. Maximiano4, V. Calvo2, B. Cantos5, M. Provencio Pulla6
  • 1Medical Oncology, Hospital Puerta de Hierro Majadahonda, Madrid, Spain, 28220 - Majadahonda/ES
  • 2Clinical Oncology, Hospital Universitario Puerta de Hierro Majadahond, 28222 - Majadahonda/ES
  • 3Clinical Oncology, Hospital Puerta de Hierro Majadahonda, 28220 - Madrid/ES
  • 4Servicio De Oncología Médica, Hospital Universitario Puerta de Hierro Majadahonda, Madrid/ES
  • 5Medical Oncology, Hospital Universitario Puerta de Hierro Majadahond, 28222 - Majadahonda/ES
  • 6Oncology Service, Hospital Universitario Puerta de Hierro de Majadahonda, 28222 - Madrid/ES

Abstract

Aim

Hepatitis infection has a high prevalence in patients with non-Hodgkin lymphoma. Our objective is to evaluate clinical characteristics and survival of patients diagnosed with diffuse large B-cell lymphoma (DLBCL) who are hepatitis B and/or C (HBV/HCV) positive.

Methods

We reviewed 224 patents diagnosed with DLBCL in our hospital between October 1982 and September 2013. Clinical, treatment and following items were obtained.

Results

We found 21 positive HBV and/or HCV (9.3%) [4 of them (1.78%) were both positive], and 203 (90.7%) negative virus (NV), without significant differences in baseline characteristics. 14 patients (67%) with HBV-C were diagnosed in stages III and IV, while 78 (40.1%) of NV were diagnosed in advanced stages. Significant differences were found in number of nodal regions affected, 4 in HBV/HCV positive vs 2 in NV, and in liver involvement which was greater in HBV/HCV positive (28.6% vs 10%, p = 0.028). 55.9% patients (n = 105) with NV were treated without rituximab, and 44.1 (n = 83) with rituximab, while 36.8% patients (n = 7) with positive virus were treated without rituximab, and 63.2% (n = 12) with rituximab. The others patients were treated with surgery, radiotherapy or did not receive any treatment due to poor performance status and comorbidities. Neither was any differences found with respect to response or number of relapses. We did not find significative toxicity after chemotheraphy, and there were no differences according the presence or absence of hepatitis virus. Liver toxicity was mainly grade 0-2. Liver toxicity grade 3 or more was found only in 1 patient. In the long term follow up of patients alive we did not find significative long-term liver complications grade 3 or more in any patient of the two groups. There were no differences in the study of the causes of death either. No significant differences in the relative risk of death associated with virus (HR 0.87 (CI 95% 0.40-1.89, p = 0.73) and the relative risk of events associated with virus (HR 0.96 (CI 95% 0.48-1.90, p = 0.91) were found. No significant differences were found with respect to the probability of overall or disease free survival.

Conclusions

Despite the differences found with respect to the stage, total number of nodal regions affected and liver involvement, HBV/HCV positive and VN DLBCL patients should receive the same treatment and they respond and evolve equally.

Disclosure

All authors have declared no conflicts of interest.